IP Library › Assignment 071721/0025
Patent Assignment
Reel/Frame 071721/0025

Security Interest

Recorded: 2025-06-25 Pages: 38
Assignor
REVOLUTION MEDICINES, INC.
Executed: 2025-06-23
Assignee
WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
50 SOUTH SIXTH STREET, SUITE 1290, MINNEAPOLIS, MINNESOTA, 55402
Covered Properties (190)
2,5-Disubstituted 3-Methyl Pyrazines and 2,5,6-Trisubstituted 3-Methyl Pyrazines as Allosteric SHP2 Inhibitors
Application: 18/124,352 →
Publication: US US20240116878A1
Substituted Pyrazolopyrazines, Imidazopyrazines and [1,2,4]Triazolopyrazines as Allosteric SHP2 Inhibitors
Application: 18/220,196 →
Publication: US US20240199616A1
SHP2 Inhibitor Compositions and Methods for Treating Cancer
Application: 19/090,050 →
Solid Forms of {6-[(2-Amino-3-Chloropyridin-4-Yl)Sulfanyl]-3-[(3S,4S)-4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl]-5-Methylpyrazin-2-Yl}Methanol, a SHP2 Inhibitor
Application: 17/537,113 →
Publication: US US20220298159A1
Bicyclic Heteroaryl Compounds and Uses Thereof
Application: 19/011,414 →
Publication: US US20260152516A1
SHP2 Inhibitor Dosing and Methods of Treating Cancer
Application: 17/854,721 →
Publication: US US20230070338A1
Method for Identifying New Therapeutic Agents
Application: 61/427,626 →
Identifying New Therapeutic Agents
Application: 18/648,723 →
Publication: US US20250076289A1
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 62/101,945 →
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 18/638,943 →
Publication: US US20250101031A1
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 62/101,925 →
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 18/899,370 →
Publication: US US20250121077A1
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 62/481,956 →
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 18/787,714 →
Publication: US US20250206715A1
Methods and Reagents for Analyzing Protein-Protein Interfaces
Application: 62/235,896 →
Methods and Reagents for Analyzing Protein-Protein Interfaces
Application: 18/593,086 →
Publication: US US20250085291A1
Methods and Reagents for Analyzing Protein-Protein Interfaces
Application: 62/482,018 →
Methods and Reagents for Analyzing Protein-Protein Interfaces
Application: 18/584,357 →
Publication: US US20240426833A1
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 62/894,493 →
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 62/930,489 →
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 62/783,816 →
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 18/184,766 →
Publication: US US20240139185A1
Covalent Ras Inhibitors and Uses Thereof
Application: 62/940,947 →
Covalent Ras Inhibitors and Uses Thereof
Application: 62/969,415 →
Covalent Ras Inhibitors and Uses Thereof
Application: 63/024,868 →
Covalent Ras Inhibitors and Uses Thereof
Application: 17/825,875 →
Publication: US US20230100838A1
Ras Inhibitors
Application: 62/930,394 →
Ras Inhibitors
Application: 62/951,763 →
Ras Inhibitors
Application: 63/000,375 →
Ras Inhibitors
Application: 63/043,601 →
Ras Inhibitors
Application: 19/044,266 →
Publication: US US20250368661A1
Ras Inhibitors
Application: 62/930,355 →
Ras Inhibitors
Application: 62/951,652 →
Ras Inhibitors
Application: 63/000,357 →
Ras Inhibitors
Application: 63/011,636 →
Ras Inhibitors
Application: 63/043,588 →
Ras Inhibitors
Application: 18/592,808 →
Publication: US US20240400523A1
Ras Inhibitors
Application: 62/930,406 →
Ras Inhibitors
Application: 62/951,562 →
Ras Inhibitors
Application: 63/000,355 →
Ras Inhibitors
Application: 63/043,523 →
Ras Inhibitors
Application: 18/591,721 →
Publication: US US20250051306A1
Methods for Delaying, Preventing, and Treating Acquired Resistance to Ras Inhibitors
Application: 63/041,071 →
Methods for Delaying, Preventing, and Treating Acquired Resistance to Ras Inhibitors
Application: 63/062,973 →
Methods for Delaying, Preventing, and Treating Acquired Resistance to Ras Inhibitors
Application: 63/117,417 →
Methods for Delaying, Preventing, and Treating Acquired Resistance to Ras Inhibitors
Application: 63/134,128 →
Methods for Delaying, Preventing, and Treating Acquired Resistance to Ras Inhibitors
Application: 63/192,976 →
Methods for Delaying, Preventing, and Treating Acquired Resistance to Ras Inhibitors
Application: 18/011,454 →
Publication: US US20230233569A1
Ras Inhibitors
Application: 63/078,802 →
Ras Inhibitors
Application: 63/129,231 →
Ras Inhibitors
Application: 63/184,412 →
Ras Inhibitors
Application: 63/192,775 →
Ras Inhibitors
Application: 19/062,331 →
Publication: US US20250186590A1
Ras Inhibitors
Application: 19/070,930 →
Publication: US US20250195662A1
Ras Inhibitors
Application: 19/068,133 →
Publication: US US20250242029A1
Ras Inhibitors
Application: 19/196,483 →
Publication: US US20250319187A1
Ras Inhibitors
Application: 19/196,471 →
Publication: US US20250255964A1
Covalent Ras Inhibitors and Uses Thereof
Application: 63/184,500 →
Covalent Ras Inhibitors and Uses Thereof
Application: 18/501,211 →
Publication: US US20240262847A1
Ras Inhibitors
Application: 63/184,599 →
Ras Inhibitors
Application: 18/762,805 →
Publication: US US20250145643A1
Ras Inhibitors
Application: 63/184,618 →
Ras Inhibitors
Application: 19/003,004 →
Publication: US US20250361245A1
Methods for Inhibiting Ras
Application: 63/192,837 →
Methods for Inhibiting Ras
Application: 18/518,027 →
Publication: US US20240277796A1
Ras Inhibitors
Application: 63/254,013 →
Ras Inhibitors
Application: 18/947,833 →
Publication: US US20250074923A1
Ras Inhibitors
Application: 63/298,098 →
Ras Inhibitors
Application: 18/769,009 →
Publication: US US20250197423A1
Methods for Treating Immune Refractory Lung Cancer
Application: 63/317,649 →
Methods for Treating Immune Refractory Lung Cancer
Application: 18/819,406 →
Publication: US US20250009753A1
Ras Inhibitors
Application: 63/351,146 →
Ras Inhibitors
Application: 63/455,649 →
Ras Inhibitors
Application: 18/973,320 →
Publication: US US20250129097A1
Methods of Treating a Ras Related Disease or Disorder
Application: 63/526,781 →
Methods of Treating a Ras Related Disease or Disorder
Application: 63/618,731 →
Methods of Treating a Ras Related Disease or Disorder
Application: 18/771,135 →
Publication: US US20250041295A1
Methods of Treating a Ras Related Disease or Disorder
Application: 19/219,571 →
Publication: US US20250345328A1
Methods for Treating Cancer
Application: 63/415,635 →
Composition Comprising a First Ras Inhibitor, Second Ras Inhibitor and a SHP2 Inhibitor for Use in the Treatment of Cancer
Application: 19/120,279 →
Publication: US US20260144799A1
Compounds, Complexes, and Methods for Their Preparation and of Their Use
Application: 63/424,079 →
Compounds, Complexes, and Methods for Their Preparation and of Their Use
Application: 19/200,842 →
Publication: US US20250269037A1
Ras Inhibitors
Application: 63/457,859 →
Ras Inhibitors
Application: 63/457,850 →
Ras Inhibitors
Application: 63/611,585 →
Ras Inhibitors
Application: 63/624,178 →
Crystalline Forms of Ras Inhibitors, Compositions Containing the Same, and Methods of Use Thereof
Application: 63/459,290 →
Crystalline Forms of Ras Inhibitors, Compositions Containing the Same, and Methods of Use Thereof
Application: 18/634,034 →
Publication: US US20240352036A1
Crystalline Forms of Ras Inhibitors, Compositions Containing the Same, and Methods of Use Thereof
Application: 63/459,403 →
Crystalline Forms of Ras Inhibitors, Compositions Containing the Same, and Methods of Use Thereof
Application: 18/634,289 →
Publication: US US20240352038A1
Synthesis of Ras Inhibitors
Application: 63/459,385 →
Synthesis of Ras Inhibitors
Application: 18/634,246 →
Publication: US US20240383920A1
Synthesis of Ras Inhibitors
Application: 63/459,435 →
Synthesis of Ras Inhibitors
Application: 18/634,098 →
Publication: US US20240368190A1
Compositions for Inducing Ras Gtp Hydrolysis and Uses Thereof in Combination with Ras(Off) Inhibitors
Application: 63/455,672 →
Compositions for Inducing Ras Gtp Hydrolysis and Uses Thereof
Application: 63/528,255 →
Combination Therapy for a Ras Related Disease or Disorder
Application: 63/464,023 →
Combination Therapy for a Ras Related Disease or Disorder
Application: 63/545,097 →
Combination Therapy for a Ras Related Disease or Disorder
Application: 63/551,254 →
Ras Inhibitors
Application: 63/469,283 →
Methods of Treating a Ras Protein-Related Disease or Disorder
Application: 63/531,175 →
Methods of Treating a Ras Protein-Related Disease or Disorder
Application: 63/543,420 →
Methods of Treating a Ras Protein-Related Disease or Disorder
Application: 63/618,783 →
Methods of Treating a Ras Protein-Related Disease or Disorder
Application: 18/795,852 →
Publication: US US20250049810A1
Synthesis of Ras Inhibitors
Application: 63/542,112 →
Synthesis of Ras Inhibitors
Application: 63/560,883 →
Synthesis of Ras Inhibitors
Application: 18/904,234 →
Publication: US US20250115551A1
Methods of Treating a Ras Protein-Related Disease or Disorder
Application: 63/710,296 →
Methods of Treating a Ras Protein-Related Disease or Disorder
Application: 63/794,157 →
Ras Inhibitors
Application: 63/543,841 →
Ras Inhibitors
Application: 63/611,600 →
Ras Inhibitors
Application: 63/638,805 →
Ras Inhibitors
Application: 18/913,242 →
Publication: US US20250154171A1
Ras Inhibitors
Application: 63/551,943 →
Ras Inhibitors
Application: 63/743,449 →
Peptide Conjugates
Application: 63/575,095 →
Peptide Conjugates
Application: 63/575,310 →
Methods for Predicting Response to a Ras(on) Inhibitor and Combination Therapies
Application: 63/631,881 →
Ras Inhibitors
Application: 63/648,875 →
Ras Inhibitors
Application: 63/736,143 →
Ras Inhibitors
Application: 63/790,944 →
Synthesis of Ras Inhibitors
Application: 63/700,982 →
Ras Inhibitors
Application: 63/733,538 →
Methods of Treating a Ras Protein-Related Disease or Disorder
Application: 63/657,527 →
Methods of Treating a Ras Protein-Related Disease or Disorder
Application: 63/662,775 →
Methods of Treating a Ras Protein-Related Disease or Disorder
Application: 19/230,256 →
Publication: US US20250375445A1
Ras Inhibitors
Application: 63/665,587 →
Ras Inhibitors
Application: 63/698,358 →
Ras Inhibitors
Application: 63/772,107 →
Ras Inhibitors
Application: 63/816,145 →
Synthesis of Ras Inhibitors
Application: 63/743,017 →
Therapeutic Compositions and Methods
Application: 63/662,756 →
Methods of Treating a Ras Related Disease or Disorder
Application: 63/670,191 →
Methods of Treating a Ras Related Disease or Disorder
Application: 63/670,221 →
Methods of Treating a Ras Related Disease or Disorder
Application: 63/670,216 →
Use of Ras Inhibitor for Treating Pancreatic Cancer
Application: 63/670,510 →
Use of Ras Inhibitor for Treating Pancreatic Cancer
Application: 63/680,332 →
Use of Ras Inhibitor for Treating Pancreatic Cancer
Application: 63/709,147 →
Use of Ras Inhibitor for Treating Pancreatic Cancer
Application: 63/763,098 →
Ras Inhibitors
Application: 63/688,562 →
Compositions and Methods for Treating Lung Cancer
Application: 63/699,441 →
Synthesis of Ras Inhibitors
Application: 63/705,811 →
Synthesis of Ras Inhibitors
Application: 63/736,868 →
Ras Inhibitors
Application: 63/709,587 →
Use of Ras Inhibitors for Treating Cancer
Application: 63/710,273 →
Use of Ras Inhibitors for Treating Cancer
Application: 63/761,346 →
Use of Ras Inhibitors for Treating Cancer
Application: 63/794,110 →
Ras Inhibitors
Application: 63/719,536 →
Ras Inhibitors
Application: 63/723,453 →
Ras Inhibitors
Application: 63/728,977 →
Ras Inhibitors
Application: 63/750,145 →
Ras Inhibitors
Application: 63/806,163 →
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
Application: 18/651,408 →
Publication: US US20250108117A1
C26-Linked Rapamycin Analogs as Mtor Inhibitors
Application: 18/298,313 →
Publication: US US20240166667A1
Synthesis of Rapamycin Analog Compounds
Application: 18/377,670 →
Publication: US US20240174615A1
Methods of Treating Cancer with an Mtor Inhibitor
Application: 18/324,050 →
Publication: US US20240082249A1
Methods of Treating Cancer with an Mtor Inhibitor
Application: 18/886,780 →
Publication: US US20250114364A1
Use of SOS1 Inhibitors with Mtor Inhibitors to Treat Cancers
Application: 18/559,932 →
Publication: US US20250134891A1
SHP2 Inhibitor Compositions and Methods for Treating Cancer
Application: 18/655,511 →
Publication: US US20250090532A1
2,5-Disubstituted 3-Methyl Pyrazines and 2,5,6-Trisubstituted 3-Methyl Pyrazines as Allosteric SHP2 Inhibitors
Application: 16/228,324 →
Publication: US US20190210977A1
2,5-Disubstituted 3-Methyl Pyrazines and 2,5,6-Trisubstituted 3-Methyl Pyrazines as Allosteric SHP2 Inhibitors
Application: 16/905,884 →
Publication: US US20210101870A1
Substituted Pyrazolopyrazines, Imidazopyrazines and [1,2,4]Triazolopyrazines as Allosteric SHP2 Inhibitors
Application: 16/518,798 →
Publication: US US20200017511A1
SHP2 Inhibitor Compositions and Methods for Treating Cancer
Application: 16/810,525 →
Publication: US US20200368238A1
Solid Forms of {6-[(2-Amino-3-Chloropyridin-4-Yl)Sulfanyl]-3-[(3S,4S)-4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl]-5-Methylpyrazin-2-Yl}Methanol, a SHP2 Inhibitor
Application: 17/187,504 →
Publication: US US20210253574A1
Bicyclic Heteroaryl Compounds and Uses Thereof
Application: 17/133,340 →
Bicyclic Heteroaryl Compounds and Uses Thereof
Application: 18/045,647 →
Publication: US US20230365605A1
Identifying New Therapeutic Agents
Patent: 9,428,845 →
Application: 13/337,875 →
Identifying New Therapeutic Agents
Application: 15/226,480 →
Publication: US US20160341719A1
Identifying New Therapeutic Agents
Application: 16/227,828 →
Publication: US US20190271691A1
Identifying New Therapeutic Agents
Application: 17/129,571 →
Publication: US US20220082556A1
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 15/542,350 →
Publication: US US20180273544A1
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 16/700,200 →
Publication: US US20200347074A1
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 17/345,570 →
Publication: US US20220144849A1
Compounds That Participate in Cooperative Binding and Uses Thereof
Application: 14/991,403 →
Publication: US US20160199506A1
Methods and Reagents for Analyzing Protein-Protein Interfaces
Patent: 9,989,535 →
Application: 15/282,430 →
Publication: US US20170097359A1
Methods and Reagents for Analyzing Protein-Protein Interfaces
Application: 15/974,921 →
Publication: US US20180252726A1
Methods and Reagents for Analyzing Protein-Protein Interfaces
Application: 15/974,923 →
Publication: US US20180259535A1
Ras Inhibitors
Application: 17/088,986 →
Publication: US US20210130369A1
Ras Inhibitors
Application: 17/089,035 →
Publication: US US20210130303A1
Ras Inhibitors
Application: 18/161,266 →
Publication: US US20230234929A1
Ras Inhibitors
Application: 17/088,848 →
Publication: US US20210130326A1
Ras Inhibitors
Application: 17/476,269 →
Publication: US US20220105185A1
Ras Inhibitors
Application: 18/188,966 →
Publication: US US20230226186A1
Ras Inhibitors
Application: 17/737,218 →
Publication: US US20220396589A1
Ras Inhibitors
Application: 17/938,890 →
Publication: US US20230303591A1
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
Application: 16/831,579 →
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
Application: 17/083,172 →
Publication: US US20210338824A1
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
Application: 17/733,755 →
Publication: US US20230055672A1
C26-Linked Rapamycin Analogs as Mtor Inhibitors
Application: 17/086,169 →
Publication: US US20220340596A1
Methods of Treating Cancer with an Mtor Inhibitor
Application: 18/506,061 →
Publication: US US20240100056A1
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Apr 14, 2015
From: VERDINE, GREGORY LAWRENCE; BOWMAN, BRIAN ROGER; SOWA, MATHEW EDWARD; BLODGETT, JOSHUA ALAN VAN DYKE
To: WARP DRIVE BIO, LLC
Reel/Frame 035405/0808 →
Assignment of Assignor's Interest Apr 14, 2015
From: VERDINE, GREGORY LAWRENCE; NICHOLS, MATTHEW JAMES; STILES, DYLAN TALBOT; ANTHONY, NEVILLE JOHN
To: WARP DRIVE BIO, LLC
Reel/Frame 035406/0374 →
Assignment of Assignor's Interest Nov 6, 2015
From: VERDINE, GREGORY L.; NICHOLS, M. JAMES; TOWNSON, SHARON A.; SHIGDEL, UDDHAV KUMAR
To: WARP DRIVE BIO, LLC
Reel/Frame 036976/0893 →
Change of Name Mar 8, 2016
From: WARP DRIVE BIO, LLC
To: WARP DRIVE BIO, INC.
Reel/Frame 038040/0639 →
Corrective Assignment to Correct the Nature of Conveyance Previously Recorded on Reel 038040 Frame 0639. Assignor(S) Hereby Confirms the Certificate of Incorporation. Apr 5, 2016
From: WARP DRIVE BIO, INC.
To: WARP DRIVE BIO, INC.
Reel/Frame 038361/0533 →
Certificate of Merger Apr 5, 2016
From: WARP DRIVE BIO, LLC
To: WARP DRIVE BIO, INC.
Reel/Frame 038358/0586 →
Assignment of Assignor's Interest Jul 18, 2018
From: MULVIHILL, MARK J.; JIN, MEIZHONG
To: WARP DRIVE BIO, INC.
Reel/Frame 046380/0364 →
Assignment of Assignor's Interest Jul 18, 2018
From: MULVIHILL, MARK JOSEPH; JIN, MEIZHONG
To: WARP DRIVE BIO, INC.
Reel/Frame 046571/0028 →
Assignment of Assignor's Interest Aug 21, 2018
From: PERL, NICHOLAS
To: WARP DRIVE BIO, INC.
Reel/Frame 046650/0063 →
Change of Name Nov 14, 2018
From: WARP DRIVE BIOSYNTHETICS
To: WARP DRIVE BIO, LLC
Reel/Frame 047536/0104 →
Assignment of Assignor's Interest Mar 15, 2019
From: JIN, MEIZHONG; PERL, NICHOLAS; KOHLMANN, ANNA; YIN, NING
To: WARP DRIVE BIO, INC.
Reel/Frame 048609/0761 →
Assignment of Assignor's Interest Apr 3, 2019
From: KOLTUN, ELENA S.; GILL, ADRIAN L.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 048778/0465 →
Assignment of Assignor's Interest Sep 24, 2019
From: WARP DRIVE BIO, INC.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 050473/0976 →
Assignment of Assignor's Interest Nov 4, 2019
From: JIN, MEIZHONG; PERL, NICHOLAS; YIN, NING; AHN, JAE YOUNG
To: WARP DRIVE BIO, INC.
Reel/Frame 050902/0350 →
Assignment of Assignor's Interest Nov 4, 2019
From: KOHLMANN, ANNA; LOWE, JASON T.; MULVIHILL, MARK JOSEPH
To: WARP DRIVE BIO, INC.
Reel/Frame 050902/0418 →
Assignment of Assignor's Interest Nov 19, 2019
From: KOLTUN, ELENA S.; GILL, ADRIAN L.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 051050/0231 →
Assignment of Assignor's Interest Nov 26, 2019
From: WARP DRIVE BIO, INC.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 051114/0988 →
Assignment of Assignor's Interest Dec 13, 2019
From: KOLTUN, ELENA S.; GILL, ADRIAN L.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 051278/0780 →
Assignment of Assignor's Interest Dec 13, 2019
From: JIN, MEIZHONG; PERL, NICHOLAS; YIN, NING; AHN, JAE YOUNG
To: WARP DRIVE BIO, INC.
Reel/Frame 051277/0925 →
Assignment of Assignor's Interest Dec 13, 2019
From: KOHLMANN, ANNA; LOWE, JASON T.; MULVIHILL, MARK JOSEPH
To: WARP DRIVE BIO, INC.
Reel/Frame 051278/0405 →
Assignment of Assignor's Interest Dec 13, 2019
From: WARP DRIVE BIO, INC.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 051278/0919 →
Assignment of Assignor's Interest Dec 17, 2019
From: KOLTUN, ELENA S.; CREGG, JAMES; AAY, NAING; BUCKL, ANDREAS
To: REVOLUTION MEDICINES, INC.
Reel/Frame 051302/0847 →
Assignment of Assignor's Interest Dec 30, 2019
From: PITZEN, JENNIFER; AGGEN, JAMES; BURNETT, G. LESLIE; GILL, ADRIAN L.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 051388/0592 →
Assignment of Assignor's Interest Feb 27, 2020
From: KOLTUN, ELENA S.; CREGG, JAMES; AAY, NAING; BUCKL, ANDREAS
To: REVOLUTION MEDICINES, INC.
Reel/Frame 051947/0387 →
Assignment of Assignor's Interest Feb 27, 2020
From: WHALEN, DANIEL M.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 051946/0044 →